Meta-Analysis Does Not Link Vitamin D Supplements, Drop in MACE
THURSDAY, June 20, 2019 -- Vitamin D supplementation is not associated with a reduced risk for major adverse cardiovascular events, according to a meta-analysis published online June 19 in JAMA Cardiology.
Mahmoud Barbarawi, M.D., from Michigan State University in Flint, and colleagues conducted a meta-analysis of randomized clinical trials to examine the correlation between vitamin D supplementation and cardiovascular disease (CVD) events and all-cause mortality. Data were included from 21 randomized clinical trials, with 83,291 patients, of whom 41,669 received vitamin D and 41,622 received placebo.
The researchers found that compared with placebo, vitamin D supplementation was not associated with reduced major adverse cardiovascular events (risk ratio [RR], 1.00; 95 percent confidence interval [CI], 0.95 to 1.06; P = 0.85) nor with the secondary end points of myocardial infarction (RR, 1.00; 95 percent CI, 0.93 to 1.08; P = 0.92), stroke (RR, 1.06; 95 percent CI, 0.98 to 1.15; P = 0.16), CVD mortality (RR, 0.98; 95 percent CI, 0.90 to 1.07; P = 0.68), or all-cause mortality (RR, 0.97; 95 percent CI, 0.93 to 1.02; P = 0.23). The results were generally consistent in subgroup analyses and analyses by sex, baseline 25-hydroxyvitamin D level, and vitamin D dosage.
"In this updated meta-analysis, which extended the earlier findings and included several recent randomized clinical trials, we did not find any association between vitamin D supplementation and cardiovascular events," the authors write.
Vitamin D and omega-3 supplements were donated by pharmaceutical companies.
© 2020 HealthDay. All rights reserved.
Posted: June 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.